Shares of Astrana Health, Inc. (NASDAQ:ASTH – Get Free Report) have been given an average recommendation of “Moderate Buy” by the nine research firms that are currently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $45.00.
A number of research analysts have recently weighed in on the company. TD Cowen raised their target price on Astrana Health from $35.00 to $45.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. Needham & Company LLC increased their price objective on shares of Astrana Health from $30.00 to $41.00 and gave the company a “buy” rating in a research note on Friday, May 8th. BTIG Research reiterated a “buy” rating and issued a $50.00 price objective on shares of Astrana Health in a research note on Tuesday, June 2nd. Barclays upgraded shares of Astrana Health from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $37.00 to $50.00 in a research note on Tuesday, May 26th. Finally, Robert W. Baird set a $45.00 price objective on shares of Astrana Health in a research note on Friday, May 8th.
View Our Latest Report on Astrana Health
Astrana Health Stock Up 1.2%
Astrana Health (NASDAQ:ASTH – Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported $0.74 earnings per share for the quarter, beating analysts’ consensus estimates of $0.29 by $0.45. Astrana Health had a return on equity of 9.22% and a net margin of 0.86%.The company had revenue of $965.10 million for the quarter, compared to analyst estimates of $949.21 million. During the same quarter last year, the company earned $0.42 earnings per share. The company’s revenue for the quarter was up 55.6% on a year-over-year basis. Sell-side analysts expect that Astrana Health will post 1.25 EPS for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the stock. Signaturefd LLC grew its position in shares of Astrana Health by 57.9% during the 4th quarter. Signaturefd LLC now owns 1,058 shares of the company’s stock valued at $26,000 after acquiring an additional 388 shares during the period. GAMMA Investing LLC grew its position in shares of Astrana Health by 144.7% during the 4th quarter. GAMMA Investing LLC now owns 1,473 shares of the company’s stock valued at $37,000 after acquiring an additional 871 shares during the period. Strs Ohio bought a new position in shares of Astrana Health during the 4th quarter valued at approximately $40,000. Tower Research Capital LLC TRC grew its position in shares of Astrana Health by 323.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,605 shares of the company’s stock valued at $115,000 after acquiring an additional 3,517 shares during the period. Finally, State of Wyoming bought a new position in Astrana Health in the 2nd quarter worth approximately $132,000. 52.77% of the stock is owned by institutional investors.
Astrana Health Company Profile
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.
Featured Stories
- Five stocks we like better than Astrana Health
- The AI Boom Has a Second Act—And It’s Playing Out in Optics
- Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback?
- 5 Tech Stocks to Buy on the July Pullback
- Is OpenAI’s IPO Delay a Warning for AI Investors?
Receive News & Ratings for Astrana Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrana Health and related companies with MarketBeat.com's FREE daily email newsletter.
